Epigenomics AG / Key word(s): Corporate Action/AGM/EGM Epigenomics AG: Capital reduction planned at a ratio of 4 : 1 09-Sep-2022 / 19:19 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.The issuer is solely responsible for the content […]
Author: mark
15. August 2022
Epigenomics AG: Notice of Loss pursuant to Sec. 92 par. 1 AktG
DGAP-News: Epigenomics AG / Key word(s): Miscellaneous/AGM/EGMEpigenomics AG: Notice of Loss pursuant to Sec. 92 par. 1 AktG 15.08.2022 / 09:00 CET/CESTThe issuer is solely responsible for the content of this announcement. Epigenomics AG: Notice of Loss pursuant to Sec. 92 par. 1 AktG Berlin, August 15, 2022 – The Executive Board of Epigenomics AG […]
10. August 2022
Epigenomics AG Reports Financial Results for the First Six Months of 2022
DGAP-News: Epigenomics AG / Key word(s): Half Year Report/Half Year ResultsEpigenomics AG Reports Financial Results for the First Six Months of 2022 10.08.2022 / 08:00 CET/CESTThe issuer is solely responsible for the content of this announcement. Epigenomics AG Reports Financial Results for the First Six Months of 2022 Berlin (Germany) and San Diego, CA (U.S.A.), […]
19. July 2022
Epigenomics AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Epigenomics AG / Total Voting Rights AnnouncementEpigenomics AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 19.07.2022 / 13:10 Total Voting Rights Announcement transmitted by DGAP – a service of EQS Group AG.The issuer is solely responsible for the content of this announcement. Publication […]
11. May 2022
Epigenomics AG Reports Financial Results for the First Quarter of 2022
DGAP-News: Epigenomics AG / Key word(s): Quarterly / Interim Statement/Quarter ResultsEpigenomics AG Reports Financial Results for the First Quarter of 2022 11.05.2022 / 08:00 The issuer is solely responsible for the content of this announcement. Epigenomics AG Reports Financial Results for the First Quarter of 2022 Berlin (Germany) and San Diego, CA (U.S.A.), May 11, […]
24. March 2022
Epigenomics AG Reports Financial Results for Fiscal Year 2021
DGAP-News: Epigenomics AG / Key word(s): Annual Report/Annual Results24.03.2022 / 08:00 The issuer is solely responsible for the content of this announcement. Epigenomics AG Reports Financial Results for Fiscal Year 2021 Total revenue of EUR 6.2 million, adjusted EBITDA of EUR -1.8 million FDA clinical trial for Epi proColon “Next Gen” expected to start with […]